September 9th 2025
Zilebesiran’s twice-yearly dosing and sustained BP reductions could offer a new therapeutic approach for adults with resistant hypertension and high CV risk who are uncontrolled on current SOC regimens.
Health Status, Not Age, Associated with Rise in Adverse Pregnancy Outcomes in the US
February 27th 2023ACC 2023. Increasing rates of adverse pregnancy outcome over the last decade are largely attributable to a woman’s health status before she gets pregnant, rather than age, according to new research.